Cheng Chang

1.2k total citations
29 papers, 747 citations indexed

About

Cheng Chang is a scholar working on Molecular Biology, Pharmacology and Immunology. According to data from OpenAlex, Cheng Chang has authored 29 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pharmacology and 6 papers in Immunology. Recurrent topics in Cheng Chang's work include Pharmacogenetics and Drug Metabolism (8 papers), Computational Drug Discovery Methods (4 papers) and Receptor Mechanisms and Signaling (4 papers). Cheng Chang is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Computational Drug Discovery Methods (4 papers) and Receptor Mechanisms and Signaling (4 papers). Cheng Chang collaborates with scholars based in United States, Singapore and Japan. Cheng Chang's co-authors include W.S. Fred Wong, Wanxing Eugene Ho, Peter W. Swaan, Sean Ekins, Li Di, Shou Ping Guan, Travis T. Wager, Phillip D. Yates, Angela C. Doran and Keith Riccardi and has published in prestigious journals such as Nature Communications, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

Cheng Chang

26 papers receiving 730 citations

Peers

Countries citing papers authored by Cheng Chang

Since Specialization

Citations

This map shows the geographic impact of Cheng Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Chang more than expected).

Fields of papers citing papers by Cheng Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Chang. The network helps show where Cheng Chang may publish in the future.

Co-authorship network of co-authors of Cheng Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng Chang. A scholar is included among the top collaborators of Cheng Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng Chang. Cheng Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects 2025 ·The AAPS Journal ·Kazuko Sagawa, Vivek S. Purohit, Vu Le, Hao‐Jui Hsu, Martin E. Dowty, Susanna Tse, Cheng Chang	4
2	Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations 2024 ·Pharmaceutical Research ·(unknown), Cheng Chang, Vivek S. Purohit, Timothy Nicholas	0
3	Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Cheng Chang, (unknown), X. Wang, Anasuya Hazra, (unknown), Timothy Nicholas, Arnab Mukherjee	3
4	Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form 2024 ·Clinical Pharmacology & Therapeutics ·Vivek S. Purohit, Kazuko Sagawa, Hao‐Jui Hsu, Joseph Kushner, Martin E. Dowty, Susanna Tse, Jian Lin, Andrew P. Blanchard, (unknown), Vu Le, Cheng Chang	5
5	Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach 2022 ·Clinical Pharmacology in Drug Development ·Arnab Mukherjee, (unknown), Cheng Chang, Timothy Nicholas, Chinyu Su, Vu Le, Joseph Kushner, (unknown)	2
6	Systems approach reveals photosensitivity and PER 2 level as determinants of clock‐modulator efficacy 2019 ·Molecular Systems Biology ·Dae Wook Kim, Cheng Chang, Xian Chen, Angela C. Doran, (unknown), Travis T. Wager, George J. DeMarco, Jae Kyoung Kim	31
7	Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189 2018 ·ACS Medicinal Chemistry Letters ·Antonia F. Stepan, Tuan P. Tran, Christopher J. Helal, Maria S. Brown, Cheng Chang, Rebecca E. O’Connor, Michael De Vivo, Shawn D. Doran, Ethan L. Fisher, Stephen Jenkinson, David A. Karanian, Bethany L. Kormos, Raman Sharma, Gregory S. Walker, (unknown), (unknown), Michael A. Brodney, Travis T. Wager, Patrick R. Verhoest, R. Scott Obach	25
8	Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition 2018 ·Molecular Pharmacology ·Cheng Chang, Kari R. Fonseca, Cheryl Li, W. Elliott Horner, Laura E. Zawadzke, (unknown), Kathryn Welch, Christine A. Strick, Brian Campbell, (unknown), Haojing Rong, Aarti Sawant‐Basak, Jennifer L. Liras, Amy B. Dounay, Jamison B. Tuttle, Patrick R. Verhoest, Tristan S. Maurer	7
9	11β-Hydroxysteroid Dehydrogenase 1 Human Tissue Distribution, Selective Inhibitor, and Role in Doxorubicin Metabolism 2018 ·Drug Metabolism and Disposition ·Xin Yang, (unknown), Sangwoo Ryu, Phillip D. Yates, Cheng Chang, Hui Zhang, Li Di	11
10	Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors 2016 ·Nature Communications ·Andrea M. Zuhl, Charles E. Nolan, Michael A. Brodney, Sherry Niessen, Kevin Atchison, Christopher Houle, David A. Karanian, Claude Ambroise, Jeffrey W. Brulet, Elizabeth M. Beck, Shawn D. Doran, Brian T. O’Neill, Christopher W. am Ende, Cheng Chang, Kieran F. Geoghegan, Graham M. West, Joshua C. Judkins, Xinjun Hou, David Riddell, Douglas S. Johnson	59
11	Preclinical Evaluation of ¹⁸F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme 2016 ·Journal of Nuclear Medicine ·Laigao Chen, Nabeel Nabulsi, Mika Naganawa, Kenneth Zasadny, Marc B. Skaddan, Lei Zhang, Soheila Najafzadeh, (unknown), Christopher J. Helal, Tracey Boyden, Cheng Chang, Jim Ropchan, Richard E. Carson, Anabella Villalobos, Yiyun Huang	11
12	Plasma Protein Binding of Challenging Compounds 2015 ·Journal of Pharmaceutical Sciences ·Keith Riccardi, (unknown), Phillip D. Yates, Cheng Chang, (unknown), Mark Niosi, Jian Lin, Li Di	86
13	Anti-allergic actions of rottlerin from Mallotus philippinensis in experimental mast cell-mediated anaphylactic models 2013 ·Phytomedicine ·Tze Khee Chan, David S.W. Ng, Cheng Chang, Shou Ping Guan, (unknown), W.S. Fred Wong	7
14	Modeling and Validating Chronic Pharmacological Manipulation of Circadian Rhythms 2013 ·CPT Pharmacometrics & Systems Pharmacology ·Jae Kyoung Kim, Daniel B. Forger, M. Marconi, Douglas E. Wood, Angela C. Doran, Travis T. Wager, Cheng Chang, (unknown)	41
15	Anti‐allergic action of anti‐malarial drug artesunate in experimental mast cell‐mediated anaphylactic models 2012 ·Allergy ·Cheng Chang, (unknown), (unknown), (unknown), Wanxing Eugene Ho, (unknown), Jin‐Song Bian, H. Y. A. Lau, W.S. Fred Wong	54
16	Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans 2011 ·The AAPS Journal ·Cheng Chang, Wonkyung Byon, Yifeng Lu, Leslie K. Jacobsen, Lori L. Badura, Aarti Sawant‐Basak, Emily Miller, Jing Liu, Sarah Grimwood, Ellen Q. Wang, Tristan S. Maurer	36
17	Anti-Malarial Drug Artesunate Attenuates Experimental Allergic Asthma via Inhibition of the Phosphoinositide 3-Kinase/Akt Pathway 2011 ·PLoS ONE ·Cheng Chang, Wanxing Eugene Ho, Fera Y. Goh, Shou Ping Guan, Li Ren Kong, Wen-Qi Lai, Bernard P. Leung, W.S. Fred Wong	97
18	The Development and Validation of a Computational Model to Predict Rat Liver Microsomal Clearance 2009 ·Journal of Pharmaceutical Sciences ·Cheng Chang, David B. Duignan, (unknown), Pil H. Lee, George S. M. Cowan, Eric Gifford, Charles J. Stankovic, Christopher Lepsy, Chad Stoner	16
19	Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure 2007 ·Pharmaceutical Research ·Akash Khandelwal, Praveen M. Bahadduri, Cheng Chang, James E. Polli, Peter W. Swaan, Sean Ekins	43
20	Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites 2007 ·Molecular Pharmacology ·Sean Ekins, Cheng Chang, Sridhar Mani, Matthew D. Krasowski, Erica J. Reschly, Manisha Iyer, Vladyslav Kholodovych, Ni Ai, William J. Welsh, Michael Sinz, Peter W. Swaan, Rachana Patel, Kenneth Bachmann	123

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact